Compare TIC & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIC | PHVS |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | Switzerland |
| Employees | 12760 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | N/A | 2020 |
| Metric | TIC | PHVS |
|---|---|---|
| Price | $8.92 | $30.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | $11.20 | ★ $41.82 |
| AVG Volume (30 Days) | ★ 2.6M | 351.0K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $44.09 | N/A |
| Revenue Next Year | $4.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.36 | $15.51 |
| 52 Week High | $14.94 | $33.33 |
| Indicator | TIC | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 50.09 | 52.99 |
| Support Level | $6.55 | $24.73 |
| Resistance Level | $9.21 | $31.14 |
| Average True Range (ATR) | 0.49 | 1.68 |
| MACD | -0.09 | 0.05 |
| Stochastic Oscillator | 18.65 | 41.73 |
TIC Solutions Inc is a provider of tech-enabled Testing, Inspection, Certification and Compliance (TICC), engineering, and geospatial services. It provides mission-critical services that are essential to the safety, reliability, and efficiency of industrial assets, buildings and public infrastructure. The company's services are often non-discretionary and are driven by regulatory requirements, customer risk management policies, and the need to extend the useful life of critical assets. It operates in North America and serve both public- and private-sector clients. Its public-sector clients include federal, state, and municipal agencies, public utilities, and environmental regulators. Its private-sector clients span industrial, infrastructure, construction, and real estate end markets.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.